Comparative Rx Economic Claims Without Head-to-Head Trials Risky – J&J’s Jimenez

Johnson & Johnson Associate General Counsel Freddy Jimenez acknowledges a continued reluctance among biopharmaceutical companies to make health care economic claims in the absence of further guidance from FDA.